List of Excipients in Branded Drug AZULFIDINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0101	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0101	POVIDONE
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0101	SILICON DIOXIDE
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0101	STARCH, CORN
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0102	CARNAUBA WAX
Pfizer Laboratories Div Pfizer Inc	AZULFIDINE	sulfasalazine	0013-0102	CELLACEFATE

Azulfidine Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Azulfidine is the branded form of sulfasalazine, an oral anti-inflammatory and immunomodulatory drug used primarily for ulcerative colitis and rheumatoid arthritis. Its commercial formulation opportunity is concentrated in three areas: generic substitution, enteric and colon-targeted delivery, and differentiated excipient systems that improve dissolution, stability, swallowability, or gastrointestinal tolerability.

The immediate-release Azulfidine tablet and Azulfidine EN-tabs delayed-release tablet should be treated as separate formulation platforms. The EN-tabs product depends on a pH-sensitive barrier to delay release until the intestinal tract, making coating composition, process control, dissolution testing, and manufacturing scale-up more commercially important than the core tablet excipients.

What is Azulfidine and which formulations are commercially relevant?

Azulfidine contains sulfasalazine, a conjugated molecule that is cleaved by colonic bacteria into sulfapyridine and 5-aminosalicylic acid. The product is available in immediate-release and delayed-release tablet forms. Azulfidine EN-tabs is designed to reduce early release in the stomach and upper gastrointestinal tract.[1]

Product	Active ingredient	Dosage form	Primary formulation issue	Commercial relevance
Azulfidine	Sulfasalazine	Immediate-release tablet	Wetting, disintegration, dissolution, tablet robustness	Conventional generic competition
Azulfidine EN-tabs	Sulfasalazine	Delayed-release tablet	Enteric protection and intestinal release	Higher technical barrier and differentiation potential
Generic sulfasalazine	Sulfasalazine	Immediate-release and delayed-release tablets	Bioequivalence and dissolution matching	Established ANDA opportunity
Novel sulfasalazine delivery system	Sulfasalazine	Colon-targeted tablet, capsule, multiparticulate, or suspension	Site-specific release and patient usability	505(b)(2), specialty, or lifecycle strategy

Sulfasalazine is not a biologic. Biosimilar regulation therefore does not apply. Competitive products are chemical generics approved primarily through the abbreviated new drug application pathway.

What excipients are used in Azulfidine tablets?

The FDA-approved labeling identifies conventional tablet excipients for Azulfidine and pH-dependent coating-related excipients for Azulfidine EN-tabs.[1]

Azulfidine immediate-release excipient system

The listed inactive ingredients for the immediate-release tablet include:

• Colloidal silicon dioxide
• Carnauba wax
• Crospovidone
• Magnesium stearate
• Povidone
• Sodium starch glycolate
• Talc
• Titanium dioxide
• Coloring agents, including yellow pigments depending on the product presentation

The functional roles are conventional:

Excipient	Primary function	Formulation risk
Crospovidone	Superdisintegrant	Excessive compression can reduce tablet breakup
Sodium starch glycolate	Superdisintegrant	High levels can increase swelling and affect dissolution
Povidone	Binder	Molecular weight and concentration affect granule strength
Magnesium stearate	Lubricant	Over-lubrication can slow wetting and dissolution
Colloidal silicon dioxide	Glidant	Influences powder flow and content uniformity
Talc	Processing aid or anti-adherent	Particle size and purity affect manufacturability
Carnauba wax	Polishing or coating component	Can affect surface properties and release
Titanium dioxide and colorants	Opacity and product identification	May create regulatory and supply-chain constraints

The immediate-release product offers relatively low formulation complexity. A generic manufacturer can generally pursue standard direct-compression or granulation approaches, provided the finished product meets the applicable quality and bioequivalence requirements.

Azulfidine EN-tabs excipient system

The delayed-release product uses a coating system that includes cellulose acetate phthalate, along with conventional tablet excipients such as carnauba wax, colloidal silicon dioxide, magnesium stearate, povidone, sodium starch glycolate, talc, titanium dioxide, and colorants.[1]

Cellulose acetate phthalate is the key commercial excipient in the EN-tabs platform. It is an enteric polymer that remains relatively intact under acidic gastric conditions and dissolves more readily at higher intestinal pH. Performance depends on polymer grade, substitution pattern, coating weight, plasticization, film uniformity, tablet geometry, and storage conditions.

What excipient strategy is required for Azulfidine EN-tabs?

The core strategy is to control acid resistance without delaying intestinal release excessively. A coating that is too thin or discontinuous can release sulfasalazine prematurely in the stomach. A coating that is too thick, insufficiently plasticized, or poorly dispersed can delay release beyond the intended site.

A commercial formulation program should evaluate:

1. Acid-stage protection.
2. Transition from acidic to intestinal pH.
3. Release rate after pH transition.
4. Coating adhesion and mechanical durability.
5. Stability under accelerated and long-term storage.
6. Tablet-to-tablet coating uniformity.
7. Effect of coating on dissolution after compression and packaging.
8. Compatibility between the core tablet and enteric polymer.

The formulation should not be optimized only against a single dissolution point. A robust development program should map the entire dissolution profile and test sensitivity to manufacturing variables.

Core-tablet optimization

The core tablet must have sufficient mechanical strength to withstand coating while retaining rapid disintegration after the enteric film dissolves. Excessive hardness, high lubricant levels, or low porosity can produce delayed post-coating release even when the enteric polymer performs correctly.

Useful development variables include:

• Crospovidone versus sodium starch glycolate ratio
• Povidone concentration and grade
• Magnesium stearate blending time
• Granule moisture
• Compression force
• Tablet porosity
• Core friability
• Film-coating weight gain
• Plasticizer concentration
• Spray rate and inlet temperature

A formulation with a low coating weight may reduce cost and processing time, but it has less tolerance for tablet-edge defects and coating variability. A thicker coating can improve acid protection but increase batch-cycle time and the risk of delayed intestinal release.

What commercial opportunities exist for Azulfidine excipients?

1. Generic immediate-release tablets

The immediate-release product is the lowest-barrier opportunity. The most commercially relevant excipient strategies are:

• Direct compression using high-functionality excipients
• Low-dose lubricant systems to protect dissolution
• Robust superdisintegrant combinations
• Reduced dust and improved flow for high-throughput manufacturing
• Colorant substitution where permitted
• Excipient sourcing from multiple qualified suppliers

The main competitive advantage is likely to come from manufacturing cost, supply reliability, and regulatory execution rather than proprietary excipient technology.

2. Generic delayed-release tablets

Azulfidine EN-tabs presents a more defensible technical opportunity because the product must reproduce delayed-release behavior. Potential value exists in:

• Cellulose acetate phthalate coating optimization
• Alternative enteric polymers with comparable performance
• Aqueous coating systems that reduce solvent handling
• Improved coating uniformity for smaller batch sizes
• Lower-cost polymer packages
• Better stability under humidity and heat
• Multiparticulate or capsule-based delayed-release systems

Alternative polymers may include methacrylic acid copolymers, hypromellose phthalate, hypromellose acetate succinate, or polyvinyl acetate phthalate. Substitution is not automatically equivalent. The applicant must demonstrate that the finished product meets regulatory dissolution and bioequivalence requirements.

3. Colon-targeted sulfasalazine products

Sulfasalazine is commercially suited to colon-targeted delivery because bacterial cleavage in the colon contributes to its pharmacological activity. A new delivery system could combine:

• pH-sensitive polymers
• Microbiome-sensitive polysaccharides
• Time-dependent coatings
• Multiparticulates
• Compression-coated tablets
• Osmotic or capsule-based systems
• Mucoadhesive excipients

This route has greater differentiation potential than a conventional generic, but it also creates a larger clinical and regulatory burden. A 505(b)(2) application could be relevant if the sponsor relies partly on existing sulfasalazine data while pursuing a materially different formulation or delivery profile.[2]

4. Patient-centric dosage forms

Sulfasalazine tablets can present swallowing and gastrointestinal tolerability challenges. Potential lifecycle products include:

• Smaller-strength tablets
• Sprinkleable multiparticulates
• Taste-masked granules
• Oral suspensions
• Dispersible tablets
• Modified-release products with reduced dosing frequency

The commercial value depends on whether the dosage form improves adherence without changing the intended delivery site or exposure profile. Taste masking is technically important because sulfasalazine and its metabolites have strong sensory characteristics.

What patents protect Azulfidine and its excipient systems?

Azulfidine is an old small-molecule product, and the original compound and conventional tablet technology are outside their original patent terms. The principal commercial barriers are regulatory requirements, formulation know-how, manufacturing controls, and market access rather than basic composition-of-matter rights.

IP category	Likely status for Azulfidine	Commercial implication
Sulfasalazine composition of matter	Expired	No meaningful exclusivity barrier
Conventional immediate-release tablet	Generally expired or vulnerable to design-around	Standard generic competition
Original delayed-release concept	Original patent protection would be expired	Does not eliminate the need to match product performance
Current formulation patents	Must be checked in current USPTO and Orange Book records	Potential product-specific risk
Manufacturing know-how	May remain confidential rather than patented	Can affect scale-up and yield
Novel colon-targeted formulation	Potentially patentable	Main source of new formulation exclusivity

Patentability is more likely for a specific combination of polymer grade, coating architecture, release profile, particle structure, or manufacturing process than for the use of a conventional enteric polymer alone. Broad claims covering "an enteric-coated sulfasalazine tablet" would face substantial prior-art pressure.

What is the Orange Book status of Azulfidine?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and regulatory exclusivity.[3] Azulfidine's commercial position is primarily that of an established small-molecule reference product rather than a product protected by current new chemical entity exclusivity.

A generic applicant should review:

• The current Orange Book reference-listed drug entries
• Active ingredient and dosage-form records
• Any listed patents
• Pediatric exclusivity
• Product-specific FDA guidance, if available
• The reference product designated for bioequivalence studies
• Discontinued-product and marketing-status records

For an old product such as sulfasalazine, the principal pathway is generally ANDA approval. A new excipient system does not by itself create exclusivity. Exclusivity requires a qualifying regulatory event, such as approval of a new clinical indication, a qualified new formulation, or another statutory basis.

When does Azulfidine lose exclusivity?

Azulfidine's original market exclusivity has expired. Generic competition is therefore legally available, subject to FDA approval and any applicable current listed patent or regulatory protections.

The relevant commercial timeline is:

Event	Status
Original sulfasalazine product approval	Historical
Original compound and formulation exclusivity	Expired
Generic sulfasalazine approval pathway	Available
Current competition	Primarily generic and formulation-based
New formulation exclusivity	Possible only through a qualifying new product or indication

The absence of basic exclusivity does not guarantee immediate generic entry. Manufacturing capacity, bioequivalence, product quality, controlled-substance status, supply contracts, and litigation can still affect timing.

Which companies are challenging Azulfidine?

Generic sulfasalazine products have been marketed by multiple manufacturers over time. The competitive field should be evaluated through current FDA approval records, National Drug Code listings, commercial availability, and pharmacy distribution rather than historical approval alone.

For diligence purposes, the relevant competitor groups are:

• Suppliers of immediate-release sulfasalazine tablets
• Suppliers of delayed-release sulfasalazine tablets
• Contract manufacturers with enteric-coating capability
• Specialty generic companies focused on low-volume products
• Developers of colon-targeted anti-inflammatory products

Paragraph IV litigation risk is generally lower for an old product with expired core patents. Risk can increase if a sponsor obtains later patents covering a specific delayed-release formulation, dosing regimen, manufacturing process, or newly approved indication. A Paragraph IV certification against a listed patent could trigger litigation under the Hatch-Waxman framework.[4]

What generic launch risks exist for Azulfidine?

Immediate-release launch risks

The major risks are:

• Failure to match dissolution
• Inadequate tablet robustness
• Inconsistent granulation
• Magnesium stearate over-lubrication
• Colorant or excipient supply interruption
• Bioequivalence variability
• Low market size relative to launch costs

Delayed-release launch risks

The EN-tabs equivalent has more significant risks:

• Incomplete acid resistance
• Premature release caused by coating defects
• Excessive lag time after pH transition
• Batch-to-batch coating variability
• Polymer aging or moisture sensitivity
• Poor adhesion during packaging and transport
• Dissolution failure after stability storage
• Difficulty reproducing the reference product's release profile

The technical risk is highest where coating process parameters are not adequately linked to critical quality attributes.

How strong is the Azulfidine patent estate?

The legacy patent estate is weak as a barrier to conventional generic entry because sulfasalazine is an established active ingredient and the original product technology is old. The stronger protectable assets are likely to be later-generation formulation or process inventions.

A practical strength assessment is:

Asset type	Patent strength	Entry barrier
Sulfasalazine active ingredient	Low	Low
Standard immediate-release tablet	Low	Low
Conventional enteric coating	Low to moderate	Moderate technical barrier
Specific coating composition and process	Moderate	Moderate
Colon-targeted multiparticulate system	Moderate to strong if clinically differentiated	Higher
New indication or dosing regimen	Variable	Depends on claim scope and enforceability
Manufacturing know-how	Not necessarily patent-based	Can be operationally meaningful

Patent value will depend on claim construction, written description, enablement, prosecution history, prior art, and whether a competing product can design around the claimed excipient system.

How does Azulfidine compare with competing anti-inflammatory formulations?

Azulfidine has a distinct delivery logic because sulfasalazine is intended to reach the colon and undergo bacterial cleavage. Mesalamine products, by contrast, use different active-ingredient and delivery strategies, including pH-dependent coatings, time-dependent release, and multimatrix systems.

Product category	Active ingredient	Delivery emphasis	Excipient opportunity
Azulfidine immediate-release	Sulfasalazine	Systemic and colonic metabolism	Disintegration, dissolution, manufacturability
Azulfidine EN-tabs	Sulfasalazine	Delayed intestinal delivery	Enteric polymer and coating process
Mesalamine delayed-release	Mesalamine	Site-specific intestinal release	Polymer selection and release control
Mesalamine extended-release	Mesalamine	Prolonged intestinal exposure	Matrix and multiparticulate technologies
Novel colon-targeted product	Various	Microbiome, pH, or time targeting	Higher-value delivery platform

Azulfidine's low-cost generic profile limits premium pricing for routine formulations. Commercial upside is greater in products that solve tolerability, pill burden, pediatric administration, or release-location problems.

What regulatory strategy applies to a new Azulfidine formulation?

A conventional equivalent generally fits the ANDA pathway. A materially different dosage form, release mechanism, indication, or dosing regimen may require a 505(b)(2) application or a full new drug application, depending on the extent of reliance on existing data.[2]

Key regulatory considerations include:

• Reference product selection
• Comparative dissolution
• In vitro release under multiple pH conditions
• Pharmacokinetic bioequivalence where required
• Food-effect assessment
• Excipient safety and prior use
• Stability and container-closure compatibility
• Product-specific labeling
• Pediatric and geriatric administration
• Clinical relevance of altered release location

A new excipient can increase regulatory risk if it lacks sufficient precedent in the proposed route, dose, or dosage form. Novel excipients may require additional toxicology and compatibility data.

What licensing deals could create value around Azulfidine?

Licensing opportunities are more likely to arise from enabling technology than from the legacy Azulfidine brand. Attractive assets include:

• Proprietary colon-targeted coating platforms
• Low-cost aqueous enteric-coating processes
• Taste-masking systems
• Multiparticulate manufacturing
• Pediatric sprinkle technologies
• Excipient combinations with improved stability
• Contract manufacturing capacity for delayed-release tablets

A licensee would likely value freedom to operate, reproducible scale-up, regulatory history, and demonstrated dissolution performance more than broad claims directed to sulfasalazine alone.

Key Takeaways

• Azulfidine contains sulfasalazine and is marketed in immediate-release and delayed-release tablet forms.
• The immediate-release product presents a conventional, low-barrier generic opportunity.
• Azulfidine EN-tabs has greater formulation complexity because cellulose acetate phthalate and the coating process control intestinal release.
• The highest-value excipient opportunities involve enteric coatings, colon targeting, taste masking, pediatric delivery, and improved manufacturability.
• Original sulfasalazine exclusivity has expired, and the main entry barriers are regulatory execution, manufacturing capability, and market economics.
• New formulation patents may be available for specific coating architectures, release profiles, multiparticulate systems, or manufacturing processes.
• Biosimilar risk is not relevant because sulfasalazine is a small-molecule drug.
• A conventional generic is generally an ANDA opportunity; a materially differentiated product may require a 505(b)(2) strategy.

FAQs About Azulfidine Excipient Commercialization

Can cellulose acetate phthalate be replaced in an Azulfidine EN-tabs generic?

Yes, an alternative enteric polymer may be used if the finished product satisfies FDA quality, dissolution, bioequivalence, and labeling requirements. Polymer substitution can change acid resistance, intestinal release, stability, and process scale-up.

Is a new excipient combination for sulfasalazine automatically patentable?

No. Patentability requires novelty, non-obviousness, adequate disclosure, and claims directed to a sufficiently specific and defensible invention. Conventional excipients used in routine combinations face substantial prior-art risk.

Does Azulfidine have an authorized generic?

An authorized generic is a commercial and regulatory question that depends on the current manufacturer and distribution record. It should be distinguished from independently approved ANDA products because the commercial arrangements and labeling may differ.

Are sulfasalazine oral suspensions commercially attractive?

They can be attractive for pediatric, geriatric, or dysphagia populations, but taste masking, suspension stability, dosing uniformity, preservative selection, and patient acceptance are material development issues.

Can a colon-targeted sulfasalazine formulation receive new market exclusivity?

Potentially. A qualifying new formulation or indication may support statutory exclusivity if it satisfies FDA requirements. Any exclusivity would attach to the approved innovation, not revive exclusivity for the legacy Azulfidine product.

References

1. U.S. Food and Drug Administration. (n.d.). Azulfidine and Azulfidine EN-tabs prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.